Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024, while full-year revenue was $12 billion, reflecting a 9% growth versus 2024 [32][33] - Non-GAAP net income for Q4 2025 was $1.3 billion, up 24% year-over-year, resulting in earnings per share of $5.03, a 26% increase compared to the prior year [37] - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [37] Business Line Data and Key Metrics Changes - Cystic fibrosis (CF) therapies generated full-year 2025 growth of 7% globally, with U.S. CF revenue growing 11% year-over-year [32][33] - CASGEVY achieved $54 million in revenue in Q4 and $116 million for the full year 2025, indicating strong patient initiations and first cell collections [34] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, with significant growth in quarterly prescriptions since its launch [34][35] Market Data and Key Metrics Changes - The CF population has seen a 3% annual increase over the last five years, contributing to revenue growth [20] - In Europe, reimbursement for ALYFTREK has been secured in key countries, enhancing market access [21] - The company has engaged with payers covering over 210 million lives regarding the renal pipeline, indicating strong interest and education on IgAN [60] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise [6][29] - The renal pipeline is expected to rival the scale of the CF business, with a focus on patient-centric approaches and securing reimbursement [29][30] - The company is committed to serial innovation and comprehensive patient support programs to enhance access to its therapies [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained growth through commercial execution and innovation [6] - The guidance for 2026 anticipates total revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [38] - The company expects combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as it continues to invest in its late-stage clinical pipeline [39] Other Important Information - The company has initiated a rolling BLA submission for povetacicept in IgAN, with breakthrough therapy designation granted by the FDA [11][12] - The company plans to double the size of its field force for JOURNAVX in Q2 2026 to drive prescription growth [26] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to pove - Management indicated that while low IgG levels are expected, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [43][44] Question: Guidance details for CF component and ALYFTREK performance - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, while noting strong international launch contributions for ALYFTREK [49][51][52] Question: Payer access and reimbursement for pove - Management reported positive engagements with payers, indicating strong interest in the product and ongoing discussions to ensure access [59][60] Question: Expected results on proteinuria for pove - Management emphasized the importance of proteinuria response magnitude, referencing RUBY-3 results as a benchmark for expected outcomes in the RAINIER trial [62][64] Question: Rationale for studying pove in generalized myasthenia gravis - Management highlighted the significant patient population and limitations of current treatments, positioning pove as a potentially superior option due to its mechanism of action [70][72]